ReGen Biologics Inc. (RGBOQ) は上場企業です ヘルスケア セクターの Medical - Instruments & Supplies 業界で事業展開. 本社所在地は Hackensack, NJ, アメリカ. 現CEOは William G. Rodkey D.V.M..
RGBOQ を有する IPO日 1996-06-28, 15 名の正社員, に上場 Other OTC, 時価総額 $97.00.
ReGen Biologics Inc. designs, develops, manufactures, and markets medical devices for the repair and generation of soft tissue in humans, primarily for orthopedic applications. The company's proprietary collagen matrix technology includes applications in orthopedics, general surgery, spine, cardiovascular, and drug delivery. Its products include Menaflex collagen meniscus implant device, for use in surgical procedures for the reinforcement and repair of soft tissue injuries of the medial meniscus; and SharpShooter Tissue Repair System, an instrument that allows surgeons to place needles in hard-to-reach locations of the meniscus. The company sells its products in the United States, the European Union, the Republic of South Africa, Canada, Australia, Chile, and Japan. ReGen Biologics Inc. was formerly known as Aros Corp and changed its name to ReGen Biologics Inc. in November, 2002. ReGen Biologics Inc. was founded in 1987 and is headquartered in Hackensack, New Jersey. On April 8, 2011, ReGen Biologics Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on October 14, 2011.
